Latest News about Biotech
Recent news which mentions Biotech
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
November 12, 2024
From Benzinga
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
November 12, 2024
From Benzinga
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
November 12, 2024
From Benzinga
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial
November 12, 2024
From Benzinga
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
November 12, 2024
From Benzinga
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
November 12, 2024
From Benzinga
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
November 11, 2024
From Benzinga
From Benzinga
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
November 11, 2024
From Benzinga
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
November 11, 2024
From Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
November 11, 2024
From Benzinga
FDA Gives Green Signal To Novavax's COVID-19-Influenza Combo Vaccine Late-Stage Trial
November 11, 2024
From Benzinga
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
November 11, 2024
From Benzinga
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
November 09, 2024
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.